Treatment efficacy of bemarituzumab plus mFOLFOX6 in the FIGHT East Asian subgroup was in line with or improved relative to results of other combinations in front-line gastric cancer, including PD-1/PD-L1 inhibitors and other novel targeted agents. Here, PDCD1 is linked to gastric cancer.